ASND Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -93.73% compared to Ascendis Pharma AS's net margin of --. Ascendis Pharma AS's return on equity of -880.05% beat DBV Technologies SA's return on equity of --.

Ascendis Pharma AS has a consensus price target of $221.71, signalling upside risk potential of 40.24%. On the other hand DBV Technologies SA has an analysts' consensus of $15.52 which suggests that it could grow by 66.32%. Given that DBV Technologies SA has higher upside potential than Ascendis Pharma AS, analysts believe DBV Technologies SA is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.407, which suggesting that the stock is 59.314% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $106.2M, which are larger than DBV Technologies SA quarterly revenues of --. Ascendis Pharma AS's net income of -$99.6M is lower than DBV Technologies SA's net income of -$27.1M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 23.55x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion AS has a net margin of -93.73% compared to Ascendis Pharma AS's net margin of -64.14%. Ascendis Pharma AS's return on equity of -880.05% beat Evaxion AS's return on equity of --.

Ascendis Pharma AS has a consensus price target of $221.71, signalling upside risk potential of 40.24%. On the other hand Evaxion AS has an analysts' consensus of $13.25 which suggests that it could grow by 665.9%. Given that Evaxion AS has higher upside potential than Ascendis Pharma AS, analysts believe Evaxion AS is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.407, which suggesting that the stock is 59.314% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $106.2M, which are larger than Evaxion AS quarterly revenues of $3M. Ascendis Pharma AS's net income of -$99.6M is lower than Evaxion AS's net income of -$1.9M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 23.55x versus 0.55x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of -93.73% compared to Ascendis Pharma AS's net margin of --. Ascendis Pharma AS's return on equity of -880.05% beat NuCana PLC's return on equity of --.

Ascendis Pharma AS has a consensus price target of $221.71, signalling upside risk potential of 40.24%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 257325.74%. Given that NuCana PLC has higher upside potential than Ascendis Pharma AS, analysts believe NuCana PLC is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.407, which suggesting that the stock is 59.314% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $106.2M, which are larger than NuCana PLC quarterly revenues of --. Ascendis Pharma AS's net income of -$99.6M is lower than NuCana PLC's net income of -$836.1K. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 23.55x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -93.73% compared to Ascendis Pharma AS's net margin of 37.18%. Ascendis Pharma AS's return on equity of -880.05% beat Novo Nordisk AS's return on equity of 84.88%.

Ascendis Pharma AS has a consensus price target of $221.71, signalling upside risk potential of 40.24%. On the other hand Novo Nordisk AS has an analysts' consensus of $89.76 which suggests that it could grow by 31.62%. Given that Ascendis Pharma AS has higher upside potential than Novo Nordisk AS, analysts believe Ascendis Pharma AS is more attractive than Novo Nordisk AS.

Ascendis Pharma AS has a beta of 0.407, which suggesting that the stock is 59.314% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.706%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.37% to investors and pays a quarterly dividend of $1.10 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ascendis Pharma AS quarterly revenues are $106.2M, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Ascendis Pharma AS's net income of -$99.6M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 20.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 23.55x versus 6.97x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.